Pancreatic Cancer Research

ResearcherSouth Texas Veterans Health Care SystemActive in the last 2 years

Huamin Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2038-5863; OpenAlex author ID A5101758546, A5135889704. Sources: OpenAlex.

Their work

Papers
133 (first author 6, last author 27)
Trials
0
Grants
0
Labs led
1
Collaborators
399
Papers, trials and grants by year

2011: 2 papers · 2012: 14 papers · 2013: 6 papers · 2014: 10 papers · 2015: 8 papers · 2016: 8 papers · 2017: 14 papers · 2018: 5 papers · 2019: 7 papers · 2020: 13 papers · 2021: 7 papers · 2022: 13 papers · 2023: 4 papers · 2024: 10 papers · 2025: 3 papers · 2026: 9 papers

Papers 50 of 133

  1. All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-026-72271-5↗
  2. Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/s41586-026-10488-6↗
  3. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10995-6↗
  4. Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/s41586-026-11134-x↗
  5. Clinicopathologic Characteristics of Brain Metastasis of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/pas.0000000000002470↗
  6. GFER Represents a Target for Dual Disruption of Redox Homeostasis and Reactivation of the Immune Response in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-24-4211↗
  7. DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-3849↗
  8. AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors. Co-author DOI 10.1158/2159-8290.cd-25-1119↗
  9. The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2767-9764.crc-25-0278↗
  10. Re/99mTc Tricarbonyl Phenformin Complexes Targeting Mitochondria as Pancreatic Cancer Theranostics. Co-author DOI 10.1021/acs.jmedchem.5c01760↗
  11. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae182↗
  12. KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-2024↗
  13. Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation. Co-author DOI 10.1016/j.xcrm.2024.101711↗
  14. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Co-author DOI 10.1038/s41421-024-00720-w↗
  15. Reconstitution of human PDAC using primary cells reveals oncogenic transcriptomic features at tumor onset. Co-author DOI 10.1038/s41467-024-45097-2↗
  16. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Co-author DOI 10.1038/s41467-024-47242-3↗
  17. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00505-0↗
  18. Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy. Co-author DOI 10.1053/j.gastro.2024.03.007↗
  19. Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improv… Co-author DOI 10.1097/pas.0000000000002270↗
  20. Netrin G1 Ligand is a new stromal immunomodulator that promotes pancreatic cancer Co-author DOI 10.1101/2024.05.15.594354↗
  21. Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Co-author DOI 10.1126/science.adh4567↗
  22. The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Last author DOI 10.3390/cancers16193312↗
  23. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Co-author DOI 10.1038/s43018-022-00500-z↗
  24. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Last author DOI 10.1097/pas.0000000000002013↗
  25. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Ran… Co-author DOI 10.1097/sla.0000000000005878↗
  26. Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neo… Last author DOI 10.3390/cancers15123231↗
  27. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2022.01.003↗
  28. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Co-author DOI 10.1016/j.ccell.2022.06.011↗
  29. Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2022.04.044↗
  30. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  31. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Co-author DOI 10.1016/j.molmet.2021.101426↗
  32. A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk. Co-author DOI 10.1016/j.xhgg.2021.100078↗
  33. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  34. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Socie… Co-author DOI 10.1097/pas.0000000000001853↗
  35. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  36. Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer. Co-author DOI 10.1186/s13045-022-01286-4↗
  37. Correction: Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer. Co-author DOI 10.1186/s13045-022-01321-4↗
  38. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review. First author DOI 10.21037/cco-21-175↗
  39. Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers. Last author DOI 10.3390/cells11193068↗
  40. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. Co-author DOI 10.1016/j.canlet.2020.12.008↗
  41. Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Co-author DOI 10.1016/j.ccell.2021.02.007↗
  42. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2020.11.003↗
  43. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Last author DOI 10.1016/j.pan.2021.03.018↗
  44. GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. Last author DOI 10.1016/j.pan.2021.08.006↗
  45. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  46. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗
  47. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. First author DOI 10.1007/s11605-019-04126-y↗
  48. SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. Co-author DOI 10.1016/j.ccell.2020.04.014↗
  49. Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer. Co-author DOI 10.1016/j.cell.2020.10.016↗
  50. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.03.018↗

Closest collaborators

The 25 strongest of 399 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 58 shared papers, 2014–2026 · strength 6.24
  2. Matthew H. G. Katz · 58 shared papers, 2012–2026 · strength 4.27
  3. Robert A. Wolff · 44 shared papers, 2012–2026 · strength 3.42
  4. Jason B. Fleming · 60 shared papers, 2011–2026 · strength 3.40
  5. Jeffrey E. Lee · 42 shared papers, 2012–2023 · strength 2.55
  6. Haoqiang Ying · 19 shared papers, 2014–2026 · strength 2.23
  7. Eugene Jon Koay · 23 shared papers, 2014–2025 · strength 2.13
  8. Laura R. Prakash · 19 shared papers, 2015–2026 · strength 2.03
  9. Michael P. Kim · 21 shared papers, 2011–2024 · strength 2.02
  10. Ching-Wei David Tzeng · 16 shared papers, 2014–2025 · strength 1.79
  11. Hua Wang · 19 shared papers, 2012–2026 · strength 1.78
  12. Gauri Rajani Varadhachary · 33 shared papers, 2012–2022 · strength 1.77
  13. Ronald Anthony Depinho · 17 shared papers, 2014–2026 · strength 1.68
  14. Ya’an Kang · 23 shared papers, 2012–2026 · strength 1.68
  15. Deyali Chatterjee · 22 shared papers, 2012–2024 · strength 1.52
  16. Andrea Viale · 13 shared papers, 2014–2026 · strength 1.44
  17. Giulio Francesco Draetta · 13 shared papers, 2014–2026 · strength 1.34
  18. Dan Zhao · 7 shared papers, 2023–2026 · strength 1.28
  19. Giannicola Genovese · 11 shared papers, 2014–2026 · strength 1.26
  20. Wantong Yao · 11 shared papers, 2014–2026 · strength 1.23
  21. Paul J. Chiao · 12 shared papers, 2012–2026 · strength 1.07
  22. Timothy Paul Heffernan · 11 shared papers, 2014–2026 · strength 1.04
  23. Naruhiko Ikoma · 7 shared papers, 2021–2024 · strength 0.94
  24. Mehran Taherian · 4 shared papers, 2022–2024 · strength 0.91
  25. Milind M. Javle · 14 shared papers, 2014–2023 · strength 0.89

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.